

II Innovative Medicines Initiative Information Day

Madrid, March 11th, 2008

Venue: Sala Pittaluga de la Escuela Nacional de Salud - Instituto de Salud Carlos III
(C/ Sinesio Delgado, 6, Madrid, SPAIN)

The Innovative Medicines Initiative (IMI) was formally adopted by the Council of the EU in December 2007. With a budget of € 2 billion, IMI will fund pan-European public-private partnerships in pharmaceutical research to overcome identified research bottlenecks in the drug development process and accelerate the development of safe and more effective medicines for patients. The first call for proposals will be launched in early 2008. With the aim to disseminate information and foster Spanish participation in IMI, the Institute of Health Carlos III, the Ministry of Education & Science, the Centre for the Development of Industrial Technology and the Spanish Technology Platform *Medicamentos Innovadores*, organize this meeting aimed to academia, researchers of the National Health System, regulators and companies.

Agenda (as per February 7th)

9:30 – 10:00 Welcome Authorities

Flora de Pablo. Director General, Institute of Health Carlos III, Ministry of Health
Francisco Marcellán. Secretary General of S&T Policy, Ministry of Education & Science
Maurici Lucena. Director General, Centre for the Development of Industrial Technology, Ministry of Industry, Tourism & Commerce
Humberto Arnés. Director General, FARMAINDUSTRIA.

10:00 – 11:00 General Overview of the *Innovative Medicines Initiative*

Structure and Governance. **Javier Urzay.** Industrial Coordinator of the Spanish Technology Platform *Medicamentos Innovadores*, **Isabel Noguer,** Institute of Health Carlos III.
Rules for participation and IMI Scientific Priorities for 2008. **Ferran Sanz.** Academic Coordinator of the Spanish Technology Platform *Medicamentos Innovadores*. **Rosa Rodríguez,** Ministry of Education and Science, **Cecilia Hernández***, Centre for the Development of Industrial Technology

11:00 – 11:30 Coffee Break

11:30 – 13:00 Scientific Priorities 2008: parallel sessions therapeutical areas

Room 1. <i>Brain Disorders</i>	Room 2. <i>Diabetes</i>	Room 3. <i>Respiratory Diseases</i>
<i>Pain.</i> José Miguel Vela (Esteve) <i>Psychiatric Disorders.</i> L.B.Stensbol* (Lundbeck) Celso Arango (CIBER Mental Health, Gregorio Marañón Hospital, Madrid)	<i>Islet cell research and markers for vascular endpoints.</i> Veikko Koivisto (Lilly) Fàtima Bosch (Center of Animal Biotechnology and Gene Therapy, Autonomous University, Barcelona)	<i>Severe asthma and COPD.</i> Chris Compton (Pfizer) Gonzalo de Miquel (Almirall) Alvar Agustí (CIBER Respiratory Diseases, Son Dureta Hospital, Palma de Mallorca)

13:00 – 14:30 Scientific Priorities 2008: parallel sessions horizontal areas

Room 1. <i>Safety Biomarkers.</i>	Room 2. <i>Farmacovigilance</i>	Room 3. <i>Education and Training</i>
Friedlieb Pfannkuch (Roche) Jaime Algorta (Progenika) Lisardo Boscá (Autonomous University, Madrid)	Javier Jiménez (AstraZeneca) Francisco de Abajo (Spanish Medicines Agency) Juan Tamargo (Faculty of Medicine, University Complutense, Madrid)	Jørgen Dirach (Novo Nordisk) Mabel Loza (University of Santiago de Compostela)

*To be confirmed.

Registration is free and must be made at www.medicamentos-innovadores.org. *Medicamentos Innovadores* has received grants from the Ministries of Education and Science and Industry.